Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
Details : Nova Mentis has completed production of pharmaceutical grade cGMP synthetic psilocybin 1.5 mg microdose capsules that will be used to advance the necessary research and development steps needed for successful drug regulatory approval and future commercia...
Product Name : NM-1001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 30, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Nova Mentis Life Science
Deal Size : Undisclosed
Deal Type : Agreement
Details : The pioneering Phase II clinical trial is the first human research investigating the potential of a microdose of psilocybin to improve behavioural and cognitive symptoms associated with Fragile X syndrome.
Product Name : NM-1001
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 17, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Nova Mentis Life Science
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Nova Mentis Life Science
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The psilocybin 1.5mg capsules are available for potential therapeutic use in non-ASD clinical trials, including but not limited to diabetes, heart disease, cancer, and post-traumatic stress disorder.
Product Name : NM-1001
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 10, 2022
Lead Product(s) : Psilocybine
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Nova Mentis Life Science
Deal Size : Inapplicable
Deal Type : Inapplicable